Crestline Management, L.P.
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), Crestline Management, L.P. reported 3 stock positions worth $46.3 million. Its top holding was Denali Therapeutics (DNLI) at 91.7% of the portfolio, followed by Sana Biotechnology (SANA, 4.7%) and 8X8 (EGHT, 3.6%). Compared with Q4 2025, it added to 1 and reduced 2. The biggest buy was 8X8 (EGHT, shares +0%) and the biggest sale Sana Biotechnology (SANA, shares −38%).
- Most Recent 13F
- Q2 2026
- Location
- FORT WORTH, TX
- CIK
- 0001536054
- Portfolio Value
- $46.3M (Q1 2026)
- SEC Filing
- 0001315863-26-000422 ↗ filed May 15, 2026
Holdings Value
Holdings 3 stocks · $46.3M
Portfolio Sells Q4 2025 → Q1 2026
Portfolio Buys Q4 2025 → Q1 2026
| EGHT 8X8 Inc. | Add +0.0% | 3.56% | −0.11 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 3 | $53.5M | DNLI, SANA, EGHT |
| Q1 2026Amended | 3 | $46.3M | DNLI, SANA, EGHT |
| Q4 2025 | 3 | $53.3M | DNLI, SANA, EGHT |
| Q3 2025 | 3 | $58.1M | DNLI, SANA, EGHT |
| Q2 2025 | 3 | $62.6M | DNLI, SANA, EGHT |
| Q1 2025 | 3 | $63.2M | DNLI, SANA, EGHT |
| Q4 2024 | 703 | $2.9B | IVV, NVDA, DNLI, QQQ, AMZN |
| Q3 2024 | 508 | $1.8B | SPY, DNLI, NVDA, CRM, AA |
| Q2 2024 | 158 | $1.3B | IVV, DNLI, NVDA, IWM, AAPL |
| Q1 2024 | 155 | $1.1B | DNLI, SANA, SPY, ASML, NI |